Leonard Braden Michael's Form 4 filing
Metacrine, Inc. (MTCR) · filed Nov 9, 2022
- Accession no.
- 0001567619-22-019403
- Filed
- Nov 9, 2022, 6:29 PM ET
- Trade date
- Nov 7-9, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market purchases total $68.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Leonard Braden MichaelCIK 0001373603 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 7, 2022 | Common Stock | PPurchaseAcquired | +123,954 | $0.4223F2 | +$52,345.77 | 5,848,649 | Indirect | |
| Nov 8, 2022 | Common Stock | PPurchaseAcquired | +500 | $0.40 | +$200 | 5,849,149 | Indirect | |
| Nov 9, 2022 | Common Stock | PPurchaseAcquired | +39,816 | $0.39F3 | +$15,528.24 | 5,888,965 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.407 to $0.43. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F3
The shares were purchased in multiple transactions at $0.39. Full information regarding the number of shares purchased can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.